Gut Microbiota Eubacterium callanderi Exerts Anti-Colorectal Cancer Activity

Seoung Woo Ryu1, Ji-Sun Kim1, Byeong Seob Oh1

  • 1Korean Collection for Type Cultures, Biological Resource Center, Korea Research Institute of Bioscience and Biotechnology, Jeongeup, Republic of Korea.

Microbiology Spectrum
|November 30, 2022
PubMed

Insights

Eubacterium callanderi shows anti-colorectal cancer (CRC) activity. This gut bacterium, through its cell-free supernatant, inhibits CRC cell proliferation and tumor growth in mice, suggesting potential for probiotic bacteriotherapy.

Area of Science:

  • Microbiology
  • Oncology
  • Gastroenterology

Background:

  • Gut microbiota (GM) is linked to colorectal cancer (CRC) development.
  • Metagenomic studies provide indirect evidence, lacking direct bacterial strain validation.
  • Limited understanding of specific GM strains' roles in CRC pathogenesis and therapeutic potential.

Purpose of the Study:

  • To identify novel gut bacteria with anti-CRC activity using culturomics.
  • To investigate the anti-CRC effects of Eubacterium callanderi and its active compounds.
  • To evaluate E. callanderi's potential for CRC bacteriotherapy.

Main Methods:

  • Isolation and screening of gut bacteria for anti-CRC activity.
  • Analysis of E. callanderi cell-free supernatant (EcCFS) for antiproliferative effects.
  • Biochemical analysis (HPLC, GC-MS) to identify active molecules (butyrate, GABA).
  • In vivo studies using a CT26 allograft mouse model.

Main Results:

  • EcCFS demonstrated dose-dependent, cancer cell-specific antiproliferative activity via apoptosis and cell cycle arrest.
  • Active molecules in EcCFS were heat-stable and protease-insensitive.
  • High concentrations of butyrate and 4-aminobutanoic acid (GABA) were identified as potential anti-CRC agents.
  • Oral administration of E. callanderi and EcCFS injection inhibited tumor growth in mice.

Conclusions:

  • Eubacterium callanderi exhibits significant anti-CRC activity both in vitro and in vivo.
  • The study identifies butyrate and GABA as key anti-CRC compounds produced by E. callanderi.
  • E. callanderi represents a promising candidate for developing novel probiotic-based bacteriotherapies for colorectal cancer.